NEWS
View news from our Featured Companies.
Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences
- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek...
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
Salt Lake City, Utah--(March 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment of Retinitis Pigmentosa, KIO-301....
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
A newly granted continuation patent provides additional intellectual property protection for ChromaDex's Niagen® ingredient and other nicotinamide adenine dinucleotide (NAD) precursors LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it was...
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - CUPERTINO, Calif., March 15, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH)...
S&W Seed Company to Participate in Fireside Chat at the 34th Annual Roth Conference
LONGMONT, Colo., March 14, 2022 -- S&W Seed Company (Nasdaq: SANW) announced that management will participate in a fireside chat today at the 34th Annual Roth Conference at the Ritz-Carlton in Dana Point, CA. 34th Annual Roth Conference Date: Monday, March 14,...
New Birmingham INVO Center Offers Families an Affordable Advanced Fertility Treatment Solution to Help Combat Rising Costs
SARASOTA, Fla., March 10, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available through a number of channels, including its new joint-venture owned INVO Center in...
Mogo Appoints Allan Smith as Head of Payments Subsidiary, Carta Worldwide
Former executive at Sofi/Galileo takes on expanded role Carta Worldwide 2021 payment processing volume grew over 50% to ~$8.5 billion VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), a digital payments and financial...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results
Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter. LOS...
Mogo Schedules Q4 2021 Earnings Conference Call
VANCOUVER, British Columbia - Mogo Inc. (TSX:MOGO) (NASDAQ:MOGO) ("Mogo" or the "Company"), a digital payments and financial technology company, today announced it will hold a conference call and webcast to discuss its Q4 & full-year 2021 financial results on...
Aytu BioPharma to Participate in the 34th Annual Roth Conference
ENGLEWOOD, CO / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki, chief financial officer, and Greg Pyszczymuka, chief commercial officer of Aytu...
PolyPid to Deliver Poster Presentation at SAGES 2022
Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve...
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
ENGLEWOOD, CO / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten offering of 3,030,000 shares of its common...
ZOOMD TECHNOLOGIES ANNOUNCED PRELIMINARY 4Q2021 FINANCIAL RESULTS HIGHIGHTED BY 181% YOY REVENUE GROWTH
Key Highlights- Revenues in 4Q21 are expected to be $18.6M, a year over year increase of 181%.- Adjusted EBITDA in 4Q21 is expected to be $2.7M, versus ($0.1M) loss in 4Q20.- Revenues for the full year 2021 are expected to be $52.5M, a year over year increase of...
ZOOMD TECHNOLOGIES ANNOUNCED PRELIMINARY 4Q2021 FINANCIAL RESULTS HIGHIGHTED BY 181% YOY REVENUE GROWTH
Key Highlights- Revenues in 4Q21 are expected to be $18.6M, a year over year increase of 181%.- Adjusted EBITDA in 4Q21 is expected to be $2.7M, versus ($0.1M) loss in 4Q20.- Revenues for the full year 2021 are expected to be $52.5M, a year over year increase of...
Modular Medical to Present at the Oppenheimer 32nd Annual Healthcare Conference
SAN DIEGO, CA / March 3, 2022 / Modular Medical Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today...
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
ENGLEWOOD, CO / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of...
Scientific Industries Secures New Funding to Accelerate Growth of Its Bioprocessing Business
BOHEMIA, NY / March 2, 2022 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced today that it has successfully secured approximately $3 million from new and existing...
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
ENGLEWOOD, CO / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European Commission granted orphan designation to AR101 (enzastaurin), a PKCβ...
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX in Abdominal Surgery
Unblinded Interim Analysis Expected in the Second Quarter of 2022PETACH TIKVA, Israel, March 02, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and...
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)
New Phase I research showcases NR supplementation significantly increased cerebral NAD levels, and decreased levels of inflammatory cytokines in Parkinson's disease (PD) patients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a...
PolyPid to Present at the Barclays Global Healthcare Conference
PETACH TIKVA, Israel, March 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...
SenesTech Announces ContraPest® Deployment at a Major Correctional Facility
ContraPest®, the one and only EPA approved birth control product for rats, addresses the unique challenges controlling rat populations in this unique customer segment.PHOENIX, Feb. 24, 2022 -- SenesTech, Inc. (NASDAQ: SNES) (www.senestech.com), the rodent...
Modular Medical Appoints James “Jeb” Besser as Chief Executive Officer
Lynn Vos to remain on board of directors Besser brings 25 years of experience in life sciences, technology, capital markets Company reaffirms timeline for 510(k) submission of MODD1 insulin pump to FDASAN DIEGO, CA / February 24, 2022 / Modular Medical, Inc. (the...
Mogo to Participate in the Canaccord Genuity Digital Disruptor Conference
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), a digital payments and financial technology company, today announced that Greg Feller, Co-Founder & President, will be participating in the Canaccord Genuity Digital...
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Annual Product Sales for 2021 Increased 25% over 2020PORTLAND, Maine, Feb. 22, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical...